APA (7th ed.) Citation

Miller, K. D., O'Neill, A., Dang, C., Northfelt, D., Gradishar, W., & Sledge, G. W. (2012). Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103. Cancer Research, 72(24a), 1605. https://doi.org/10.1158/0008-5472.SABCS12-P5-17-01

Chicago Style (17th ed.) Citation

Miller, K. D., A. O'Neill, C. Dang, D. Northfelt, W. Gradishar, and G. W. Sledge. "Bevacizumab (B) in the Adjuvant Treatment of Breast Cancer - First Toxicity Results from Eastern Cooperative Oncology Group Trial E5103." Cancer Research 72, no. 24a (2012): 1605. https://doi.org/10.1158/0008-5472.SABCS12-P5-17-01.

MLA (9th ed.) Citation

Miller, K. D., et al. "Bevacizumab (B) in the Adjuvant Treatment of Breast Cancer - First Toxicity Results from Eastern Cooperative Oncology Group Trial E5103." Cancer Research, vol. 72, no. 24a, 2012, p. 1605, https://doi.org/10.1158/0008-5472.SABCS12-P5-17-01.